HTLV-1; ATL; Compound screening; Cell proliferation; Apoptosis; Tax protein
Abstract :
[en] Human T cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that infects approximately 10–20 million people worldwide and causes an aggressive neoplasia (adult T-cell leukemia/lymphoma - ATL). Therapeutic approaches for the treatment of ATL have variable effectiveness and poor prognosis, thus requiring strategies to identify novel compounds with activity on infected cells. In this sense, we initially screened a small series of 25 1,2,3-triazole derivatives to discover cell proliferation inhibitors and apoptosis inducers in HTLV-1- infected T-cell line (MT-2) for further assessment of their effect on viral tax activity through inducible-tax reporter cell line (Jurkat LTR-GFP). Eight promising compounds (02, 05, 06, 13, 15, 21, 22 and 25) with activity ≥70% were initially selected, based on a suitable cell-based assay using resazurin reduction method, and evaluated towards cell cycle, apoptosis and Tax/GFP expression analyses through flow cytometry. Compound 02 induced S phase cell cycle arrest and compounds 05, 06, 22 and 25 promoted apoptosis. Remarkably, compounds 22 and 25 also reduced GFP expression in an inducible-tax reporter cell, which suggests an effect on Tax viral protein. More importantly, compounds 02, 22 and 25 were not cytotoxic in human hepatoma cell line (Huh-7). Therefore, the discovery of 3 active and non-cytotoxic compounds against HTLV-1-infected cells can potentially contribute, as an initial promising strategy, to the development process of new drugs against ATL.
Disciplines :
Oncology
Author, co-author :
dos Santos, Daiane Fernanda
Bairros de Pilger, Denise Regina
Vandermeulen, Charlotte
Khouri, Ricardo
Pedersoli Mantoani, Susimaire
Gonçalves Nunes, Paulo Sérgio
de Andrade, Peterson
Carvalho, Ivone
Casseb, Jorge
Twizere, Jean-Claude ; Université de Liège - ULiège > GIGA Molecul. Bio. of Diseases - Viral Interactomes Network
Willems, Luc ; Université de Liège - ULiège > GIGA Cancer - Cellular and Molecular Epigenetics
Gallo, R.C., History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene 24 (2005), 5926–5930, 10.1038/sj.onc.1208980.
Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77 (1980), 7415–7419, 10.1073/pnas.77.12.7415.
Yoshida, M., Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 24 (2005), 5931–5937, 10.1038/sj.onc.1208981.
Gessain, A., Cassar, O., Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3 (2012), 1–23, 10.3389/fmicb.2012.00388.
Catalan-Soares, B., Carneiro-Proietti, A.B.F., Proietti, F.A., Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I / II): Serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saúde Pública 21 (2005), 926–931, 10.1590/S0102-311X2005000300027.
Bangham, C.R., Ratner, L., How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?. Curr Opin Virol 14 (2015), 93–100, 10.1016/j.coviro.2015.09.004.
Ishitsuka, K., Tamura, K., Human T-cell leukaemia virus type i and adult T-cell leukaemia-lymphoma. Lancet Oncol 15 (2014), e517–e526, 10.1016/S1470-2045(14)70202-5.
Shimoyama, M., Diagnostic criteria and classification of clinical subtypes of adult T-Cell leukaemia-lymphoma. Br J Haematol 79 (1991), 428–437, 10.1111/j.1365-2141.1991.tb08051.x.
Tsukasaki, K., Tobinai, K., Human T-cell lymphotropic virus type i-associated adult T-cell leukemia-lymphoma: New directions in clinical research. Clin Cancer Res 20 (2014), 5217–5225, 10.1158/1078-0432.CCR-14-0572.
Marçais, A., Suarez, F., Sibon, D., et al. Therapeutic options for adult T-cell leukemia/lymphoma. Curr Oncol Rep 15 (2013), 457–464, 10.1007/s11912-013-0332-6.
Bazarbachi, A., Plumelle, Y., Ramos, J.C., et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28 (2010), 4177–4183, 10.1200/JCO.2010.28.0669.
Kinpara, S., Kijiyama, M., Takamori, A., et al. Interferon-Α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 10 (2013), 1–15, 10.1186/1742-4690-10-52.
Ishida, T., Joh, T., Uike, N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 30 (2012), 837–842, 10.1200/JCO.2011.37.3472.
Ishitsuka, K., Yurimoto, S., Kawamura, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: Interim results of postmarketing all-case surveillance. Int J Hematol 106 (2017), 522–532, 10.1007/s12185-017-2270-9.
Marino-Merlo, F., Mastino, A., Grelli, S., et al. Future perspectives on drug targeting in adult T cell. Front Microbiol 9 (2018), 1–8, 10.3389/fmicb.2018.00925.
Tanaka, A., Matsuoka, M., HTLV-1 alters T cells for viral persistence and transmission. Front Microbiol 9 (2018), 1–7, 10.3389/fmicb.2018.00461.
Boxus, M., Willems, L., Mechanisms of HTLV-1 persistence and transformation. Br J Cancer 101 (2009), 1497–1501, 10.1038/sj.bjc.6605345.
Carpentier, A., Barez, P.Y., Hamaidia, M., et al. Modes of human T cell leukemia virus type 1 transmission, replication and persistence. Viruses 7 (2015), 3603–3624, 10.3390/v7072793.
Mühleisen, A., Giaisi, M., Köhler, R., et al. Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression. Cell Death Dis 5 (2014), 1–10, 10.1038/cddis.2014.536.
Soltani, A., Isaac, S., Zahedi, F., Soleimani, A., Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother 109 (2019), 770–778, 10.1016/j.biopha.2018.10.139.
Hajj, H.E., Khalil, B., Ghandour, B., et al. Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia / lymphoma. Blood 124 (2014), 2072–2081, 10.1182/blood-2014-03-560060.
Césaire, R., Meniane, J.C., ST1926 repression of tax: ATL. Blood 124 (2014), 2009–2012, 10.1182/blood-2014-08-590489.
Prachayasittikul, V., Pingaew, R., Anuwongcharoen, N., et al. discovery of novel 1,2,3-triazole derivatives as anticancer agents using QSAR and in silico structural modification. Springerplus 4 (2015), 1–22, 10.1186/s40064-015-1352-5.
Aziz Ali, A., Gogoi, D., Chaliha, A.K., et al. Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents. Bioorganic Med Chem Lett 27 (2017), 3698–3703, 10.1016/j.bmcl.2017.07.008.
Kharb, R., Shahar Yar, M., Chander, Sharma P., Recent advances and future perspectives of triazole analogs as promising antiviral agents. Mini-Reviews Med Chem 11 (2011), 84–96, 10.2174/138955711793564051.
Mantoani, S.P., De Andrade, P., Chierrito, T.P.C., et al. Potential triazole-based molecules for the treatment of neglected diseases. Curr Med Chem 26 (2018), 4403–4434, 10.2174/0929867324666170727103901.
De Andrade, P., Mantoani, S.P., Nunes, P.S.G., et al. Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's Disease. Bioorg Med Chem 27 (2019), 931–943, 10.1016/j.bmc.2018.12.03026.
Nakano, D., Ishitsuka, K., Hatsuse, T., et al. Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: Active principles from Physalis pruinosa and structure-activity relationships with withanolides. J Nat Med 65 (2011), 559–567, 10.1007/s11418-011-0543-9.
Nakano, D., Ishitsuka, K., Ikeda, M., et al. Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (IV): Phenanthroindolizidine alkaloids from Tylophora tanakae leaves. J Nat Med 69 (2015), 397–401, 10.1007/s11418-015-0906-8.
Sales, L., De Souza, G.R., Ferreira-Silva, G., et al. YM155 induces apoptosis in p53-deficient t-acute lymphoblastic leukemia cells independent of survivin inhibition. Anticancer Drugs 28 (2017), 298–306, 10.1097/CAD.0000000000000462.
Otto, T., Sicinski, P., Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17 (2017), 93–115, 10.1038/nrc.2016.138.
Narita, T., Ishida, T., Ito, A., et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia / lymphoma. Blood 130 (2017), 1114–1125, 10.1182/blood-2016-09-741983.
Agbottah, E., Yeh, W.I., Berro, R., et al. Two specific drugs, BMS-345541 and purvalanol a induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways. AIDS Res Ther 5 (2008), 1–16, 10.1186/1742-6405-5-12.
Alais, S., Mahieux, R., Dutartre, H., Viral source-independent high susceptibility of dendritic cells to human T-cell leukemia virus type 1 infection compared to that of T lymphocytes. J Virol 89 (2015), 10580–10590, 10.1128/JVI.01799-15.
